Enfortumab Vedotin and Pembrolizumab in Cisplatin-Eligible Bladder Cancer

Overview of attention for article published in New England Journal of Medicine, July 2026

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (99th percentile)
High Attention Score compared to outputs of the same age and source (88th percentile)

Mentioned by

news: 20 news outlets
blogs: 3 blogs
twitter: 97 X users

reddit: 1 Redditor
bluesky: 15 Bluesky users

Readers on

mendeley: 58 Mendeley

So far, Altmetric has seen 3 posts from 3 blogs.

HMN 2026: How New treatment approach improves survival, reduces recurrence risk in muscle-invasive bladder cancer

Health Medicine Network, 22 Aug 2026

Credit: Pavel Danilyuk from Pexels Researchers have found that a combination of enfortumab vedotin and pembrolizumab helps…

New Combination Therapy Shows Promise for Advanced Bladder Cancer

CU Anschutz Newsroom, 06 Aug 2026

A novel combination therapy with first-in-human roots at the University of Colorado Anschutz delivered effective and durable…

Enfortumab Vedotin-Pembrolizumab More Effective for MIBC Than Cisplatin-Gemcitabine

modernclinician, 28 Jul 2026

TUESDAY, July 28, 2026 (HealthDay News) — For adults with muscle-invasive bladder cancer, the combination of enfortumab vedotin…

This page shows the most recent blog posts that mention this research output. Click here to find out how to access more activity.